IMPACT Therapeutics, Inc. discovers, develops, and commercializes therapeutics to treat cancer and other life-threatening diseases. IMPACT Therapeutics, Inc. has started several novel drug R&D projects, including PARP inhibitor, Wee1 inhibitor, other novel DDR agents and Hedgehog pathway inhibitor. The company was founded in 2009 and is based in Shanghai, China.